RespiQ
Leiden
About RespiQ
RespiQ is a healthtech startup leader in the development of portable, non-invasive breath analysis technology for early detection and management of respiratory diseases. Utilizing advanced emission spectroscopy combined with artificial intelligence, RespiQ's innovative device identifies volatile organic compounds (VOCs) in breath to detect COPD exacerbations and other conditions in real-time. With a focus on affordability, portability, and user-friendliness, RespiQ aims to democratize access to advanced diagnostics, improve patient outcomes, and reduce healthcare costs. The company's platform technology is versatile, offering potential applications beyond COPD, including asthma, lung cancer, and infectious diseases, positioning RespiQ as a leader in breath diagnostics. "The team has the perfect combination of technical and healthcare expertise to enable people to live happier healthier lives by just breathing. We are excited to see the growth of RespiQ and their journey for enabling millions to get better health advice." - Kim Oreskovic, Partner, Antler Amsterdam
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.6M
- Funding stage: Seed
- Last round: Non-Equity Assistance (Oct 2024)
- Website: respiq.com
Industries & Categories
Biotechnology, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/respiq-58767 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.